<DOC>
	<DOCNO>NCT01060670</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy INTEGRA® Dermal Regeneration Template treatment diabetic foot ulcer locate distal malleolus subject diabetes mellitus , neuropathy , without significantly compromise arterial circulation .</brief_summary>
	<brief_title>A Safety Efficacy Study INTEGRA® Dermal Regeneration Template Treatment Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Type I Type II diabetes mellitus Glycosylated hemoglobin , HbA1c , ≤ 12 % Negative serum pregnancy test screen female participant childbearing potential Willing able maintain require offloading ( applicable location ulcer ) applicable dressing change At least one DFU meet follow criterion : 1 . Ulcer diagnose fullthickness neuropathic DFU locate distal malleolus ( exclude ulcer toe include heel ) , 2 . Minimum 2cm margin qualify study ulcer ulcer specify foot ( post debridement ) , 3 . Area great equal 1 square centimeter le equal 12 square centimeter ( post debridement time randomization ) , 4 . Wagner grade 1 2 , 5 . Depth le equal 5 millimeter expose capsule , tendon bone tunneling , undermine sinus tract , 6 . Duration study ulcer least 30 day time screen visit Adequate vascular perfusion affect limb Suspected confirm signs/symptoms gangrene wound infection part limb History hypersensitivity bovine collagen and/or chondroitin . Pregnancy Previous treatment clinical protocol Participation another clinical trial involve device systematically administer investigational study drug treatment within 30 day randomization visit . Receiving scheduled receive medication treatment , opinion investigator , know interfere , affect rate quality wound heal Any unstable condition circumstance could interfere treatment regimen compliance Excessive lymphedema could interfere wound heal Unstable Charcot foot Charcot boney prominence Ulcers secondary disease diabetes Osteomyelitis necrotic soft bone Chopart amputation History bone cancer metastatic disease affect limb , radiation therapy foot , chemotherapy within 12 month prior randomization Treatment wound dressing include growth factor , engineer tissue , skin substitute within 30 day randomization schedule receive treatment study Nonstudy ulcer require treatment could treat study moist wound therapy History intercurrent illness condition ( diabetes ) would compromise safety subject , normal wound heal process Employees relatives member investigational site sponsor Size study ulcer follow debridement decrease 30 % run period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Foot Ulcer</keyword>
	<keyword>Diabetic</keyword>
	<keyword>Wound Healing</keyword>
	<keyword>Integra Dermal Regeneration Template</keyword>
	<keyword>Full Thickness</keyword>
	<keyword>Neuropathic</keyword>
	<keyword>Omnigraft</keyword>
</DOC>